Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1008

Similar articles for PubMed (Select 8961976)

1.

Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.

Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K, Vainio H.

J Natl Cancer Inst. 1996 Dec 18;88(24):1853-6.

2.

Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.

Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K.

Cancer Res. 1995 Jul 15;55(14):2981-3.

3.

Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma.

Betti M, Neri M, Ferrante D, Landi S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M, Bonassi S, Magnani C, Dianzani I.

Int J Hyg Environ Health. 2009 May;212(3):322-9. doi: 10.1016/j.ijheh.2008.08.001. Epub 2008 Oct 1.

PMID:
18838334
4.

Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations.

Neri M, Taioli E, Filiberti R, Paolo Ivaldi G, Aldo Canessa P, Verna A, Marroni P, Puntoni R, Hirvonen A, Garte S.

Int J Hyg Environ Health. 2006 Jul;209(4):393-8. Epub 2006 May 11.

PMID:
16697254
5.
6.

Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.

Okkels H, Sigsgaard T, Wolf H, Autrup H.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):225-31.

7.

NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.

van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno de Mesquita HB.

Pharmacogenetics. 2003 Jul;13(7):399-407.

PMID:
12835615
8.

N-Acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk.

Wikman H, Piirilä P, Rosenberg C, Luukkonen R, Kääriä K, Nordman H, Norppa H, Vainio H, Hirvonen A.

Pharmacogenetics. 2002 Apr;12(3):227-33.

PMID:
11927838
9.

Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2.

Godschalk RW, Dallinga JW, Wikman H, Risch A, Kleinjans JC, Bartsch H, Van Schooten FJ.

Pharmacogenetics. 2001 Jul;11(5):389-98.

PMID:
11470992
10.

N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study.

Rodrigo L, Alvarez V, Rodriguez M, Pérez R, Alvarez R, Coto E.

Scand J Gastroenterol. 1999 Mar;34(3):303-7.

PMID:
10232877
11.

Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California.

London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR.

J Natl Cancer Inst. 1995 Aug 16;87(16):1246-53.

PMID:
7563171
12.
13.

N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer.

Lee KM, Park SK, Kim SU, Doll MA, Yoo KY, Ahn SH, Noh DY, Hirvonen A, Hein DW, Kang D.

Cancer Lett. 2003 Jul 10;196(2):179-86.

PMID:
12860276
14.

Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.

Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP.

Cancer Detect Prev. 2009;32(5-6):416-23. doi: 10.1016/j.cdp.2009.02.003. Epub 2009 Mar 20.

PMID:
19303722
15.

Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.

Rouissi K, Ouerhani S, Marrakchi R, Ben Slama MR, Sfaxi M, Ayed M, Chebil M, El Gaaied AB.

Cancer Genet Cytogenet. 2009 Apr 15;190(2):101-7. doi: 10.1016/j.cancergencyto.2009.01.007.

PMID:
19380028
16.

Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.

Salagovic J, Kalina I, Stubna J, Habalová V, Hrivnák M, Valanský L, Kohút A, Biros E.

Neoplasma. 1998;45(5):312-7.

PMID:
9921921
17.

Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer.

Ateş NA, Tamer L, Ateş C, Ercan B, Elipek T, Ocal K, Camdeviren H.

Biochem Genet. 2005 Apr;43(3-4):149-63.

PMID:
15932063
18.

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N.

Lancet. 2005 Aug 20-26;366(9486):649-59.

19.

GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients.

Hou SM, Ryberg D, Fält S, Deverill A, Tefre T, Børresen AL, Haugen A, Lambert B.

Carcinogenesis. 2000 Jan;21(1):49-54.

20.

Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking.

Tsukino H, Nakao H, Kuroda Y, Imai H, Inatomi H, Osada Y, Katoh T.

Eur J Cancer Prev. 2004 Dec;13(6):509-14.

PMID:
15548945
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk